Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02526498 · ClinicalTrials.gov registry record · Phase 2
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
A Phase 2 study of Invasive Breast Carcinoma and Stage IIA Breast Cancer, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 10
- Study locations
NCT02526498 is a Phase 2 study of Invasive Breast Carcinoma and Stage IIA Breast Cancer that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 200 participants, below the 481-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (58% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT02526498, a Phase 2 study of Invasive Breast Carcinoma and Stage IIA Breast Cancer, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 10
- Study locations
Study Summary
This phase II trial studies how well accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy works in treating patients with breast cancer that has not spread beyond the breast or the axillary lymph nodes (early-stage) after surgery. Radiation therapy uses a type of energy to kill cancer cells and shrink tumors. Brachytherapy is a type of internal radiation therapy that provides radiation inside the breast to any remaining tumor cells next to the space where the tumor was removed, and is given over a shorter amount of time than standard radiation therapy. Giving accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy may reduce the overall time that radiation is delivered to the tumor cells.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- RADIATION Accelerated Partial Breast Irradiation
- RADIATION High-Dose Rate Brachytherapy
Study Locations (10)
New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital - New Brunswick
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- Montefiore Medical Center - The Bronx
- 21st Centry Oncolgy - Yonkers
Arizona
- Arizona Breast Cancer - Gilbert
California
- University of California, San Diego - La Jolla
Michigan
- William Beaumont Hospital Research Institute - Royal Oak
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- Bryn Mawr Hospital - Bryn Mawr
Utah
- Huntsman Cancer Hospital, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-07-15 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02526498
The ClinicalTrials.gov registry entry for NCT02526498 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (58% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT02526498 reports 10 study locations spanning 8 distinct geographic areas - top geographies include New Jersey, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT02526498 about?
NCT02526498 is a clinical study titled "Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery". This phase II trial studies how well accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy works in treating patients with breast cancer that has not spread beyond the breast or the axillary lymph nodes (early-stage) after surgery. Radiation therapy uses a type of en...
What is the current status of trial NCT02526498?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2015-07-15. Estimated completion is 2021-03-31.
What conditions does trial NCT02526498 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Stage IIA Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Ductal Breast Carcinoma in Situ.
What interventions are being tested in trial NCT02526498?
The interventions under investigation include: Questionnaire Administration (OTHER), Accelerated Partial Breast Irradiation (RADIATION), High-Dose Rate Brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT02526498?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02526498 being conducted?
This trial has 10 study locations across Arizona, California, Michigan, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Metformin and Nightly Fasting in Women With Early Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.